Qudexy XR (Topiramate) Patent Expiration, LOE Window & CMS Spending

Qudexy XR (Topiramate) by Upsher Smith Laboratories: FDA Orange Book LOE 2033-03-19, 15 AB generics, $5.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUpsher Smith Laboratories
FDA Application & PathwayN205122 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-03-19
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$5.0M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$3.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel